These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16768125)

  • 1. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
    Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL; Dong MH; Loomba R
    Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model.
    Toriniwa Y; Saito T; Miyajima K; Ishii Y; Uno K; Maekawa T; Matsui T; Kume S; Yamada T; Ohta T
    J Vet Med Sci; 2018 Jun; 80(6):878-885. PubMed ID: 29643297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
    Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy for non-alcoholic steatohepatitis].
    Tomita K; Hibi T
    Nihon Rinsho; 2006 Jun; 64(6):1146-51. PubMed ID: 16768123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of insulin sensitizers in NASH.
    Khashab M; Chalasani N
    Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of NAFLD.
    Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C
    Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
    Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
    Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
    Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
    Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
    Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nonalcoholic steatohepatitis].
    Ratziu V; Tahiri M; Bonyhay L
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S71-80. PubMed ID: 15959406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
    Ratziu V; Caldwell S; Neuschwander-Tetri BA
    Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones and the liver in humans.
    Yki-Järvinen H
    Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis.
    Zhang W; Xu YZ; Liu B; Wu R; Yang YY; Xiao XQ; Zhang X
    ScientificWorldJournal; 2014; 2014():603409. PubMed ID: 24558317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.